About this event

This free webinar is hosted by MedCan Support and Ananda Developments. Questions can be submitted beforehand to info@medcansupport.co.uk or through twitter #MedCanSupport.

Key topics :

1. How is prescription cannabis a move towards integrative personalized medicine?

2. How can we take the guesswork out of using CBPMs and aid better understanding?

3. What safety guidelines do we need to learn?

4. What are terpenes, phytocannabinoids and flavonoids and why does this matter to the patients?

5. Choosing safe products - what is Good Manufacturing Processes. (GMP) 

6. Importance of Certificates of Analysis (COA's)

7. Support structures and choices available to you?

8. Key obstacles to access that need to be overcome for UK families ?

9. The future with a domestic supply and the changes we'd like to see ?

This 60-90 minute panel discussion will include the following speakers ;

Expert Speakers:

Melissa Sturgess holds a BSc and an MBA and has more than 20 years of experience as a director of UK and Australian Stock Exchange quoted companies. She has a strong track record operating in complex regulatory environments. Melissa’s interest in the cannabis sector commenced in 2017 with a trip to Israel to review the medicinal cannabis research in that country. She subsequently founded UK based, AQSE quoted Ananda Developments Plc to invest in the sector and is its largest individual shareholder. Melissa was the recipient of the Executive of the Year at the Malta Cannabiz Awards in November 2019.

Matt Hughes is the Co-Founder and Director of MedCan Support, a hub for education, advocacy, research and support in the use of prescribed cannabis in paediatrics. Matt has been involved in the UK Medical Cannabis sector since early 2019 when his son Charlie was prescribed cannabis in the treatment of his severe treatment resistant epilepsy. Charlie has seen a dramatic reduction in seizures and much improved quality of life. Matt continues to campaign and advocate for population wide NHS access for children suffering with severe epilepsy and be a voice for patients and families within the growing private cannabis sector joining the executive committee of the UK Cannabis Industry Council.

Dr. Callie Seaman is a Plant Scientist and Formulation Chemist with over 20 years of experience in the hydroponic industry. She has worked with a number of licensed cannabis producers within the UK and internationally as a director and researcher helping to optimize and set up research programs around secondary metabolite production within cannabis. She first completed a degree in biomedical sciences, during which she worked for GlaxoSmithKline within the drug metabolism and pharmacokinetics department. She then went on to complete a PhD in fertilizer chemistry at Sheffield Hallam University whilst setting up a liquid fertilizer manufacturing company, formulating and taking to market a full range of products. As a patient she is passionate about educating everyone about cannabis and helping to support patients through their journey with cannabis prescription, through volunteering for organization such as MedCan Support and PLEA (Patient-Led Engagement for Access).